To examine whether tacrolimus is more effective and safe than cyclosporine (CsA) in inducing remission in patients with steroid-resistant nephrotic syndrome (SRNS).
M
anagement of idiopathic steroid-resistant nephrotic syndrome (SRNS) in children is challenging. Patients are at risk of complications of nephrotic syndrome, side effects of immunosuppressive agents, and progressive kidney disease. 1 The aim of therapy therefore is induction of remission while avoiding medicationassociated toxicity. Although multiple agents have been used in patients with SRNS, the optimal treatment regimen is not defined. A lack of prospective trials comparing the efficacy of immunosuppressive medications has resulted in the absence of treatment guidelines. Results from prospective studies, including randomized trials, suggest that treatment with oral cyclophosphamide is not effective in patients with SRNS. 2, 3, 4 Findings from observational studies comprising intravenous (IV) corticosteroids or IV cyclophosphamide showed efficacy rates ranging from 45% to 60%. 5, 6 Treatment with these agents was associated with significant side effects. During the last 2 decades, cyclosporine (CsA) has been used in patients with SRNS with efficacy rates ranging between 30% and 70%. [7] [8] [9] However, treatment with CsA is associated with nephrotox-icity and cosmetic side effects. 10, 11 Data from transplant recipients suggest that tacrolimus is a more potent immunosuppressive agent than CsA and is associated with minimal cosmetic side effects and lower risk of hypertension and dyslipidemia, 12 but increased risk of diabetes and neurotoxicity. 13 Most reports of the use of tacrolimus in patients with nephrotic syndrome are retrospective or uncontrolled and include patients with heterogeneous severity and renal histological characteristics. [14] [15] [16] Tacrolimus was found to be effective in inducing remission in 35% to 93% of patients with SRNS who were resistant to CsA.
15, 16 However, there is a lack of randomized controlled trials comparing the efficacy of these agents in patients with nephrotic syndrome. Based on the hypothesis that tacrolimus is more effective than CsA in inducing remission in patients with SRNS, we compared the efficacy and safety of 12 months of treatment with these agents.
METHODS
This study was conducted from August 2005 to July 2007 at the All India Institute of Medical Sciences (New Delhi), a referral center in north India. The study, which included 12 months each for enrollment and follow-up, was approved by the Ethics Committee; permission was also obtained from the Drug Controller General of India.
Study Population
Consecutive patients between 1 and 18 years of age with idiopathic SRNS and renal histological characteristics suggestive of minimal change disease (MCD), mesangioproliferative glomerulonephritis, or focal segmental glomerulosclerosis (FSGS) were eligible. Patients who received treatment with CsA or tacrolimus at any time or immunosuppressive agents other than prednisolone in the preceding 12 weeks were excluded. Patients with nephrotic syndrome secondary to membranoproliferative glomerulonephritis or membranous nephropathy, serum creatinine level greater than 1.5 mg/dL, estimated glomerular filtration rate 17 less than 60 mL/min/1.73 m 2 , time between onset of steroid resistance and inclusion longer than 24 months, and history of diabetes mellitus or liver disease were excluded. Written consent was obtained from either of the parents before enrollment.
Nephrotic syndrome was defined as the presence of nephrotic-range proteinuria (3ϩ or greater) by means of dipstick, spot urine protein-creatinine (Up/Uc) ratio greater than 2 g/g, hypoalbuminemia with albumin less than 2.5 g/dL, and edema. SRNS was defined as the absence of remission despite treatment with prednisolone at a dose of 2 mg/kg/d for 4 weeks. Initial resistance was the presence of steroid resistance at the onset. Patients showing remission at onset, but SRNS in a subsequent relapse, were classified as late resistance. Kidney biopsy specimens were examined by using light and immunofluorescence microscopy and categorized as MCD, mesangioproliferative glomerulonephritis, and FSGS by using standard criteria. 18 Molecular analysis was performed on all 8 exons of NPHS2 (the gene encoding podocin; GenBank accession no. AJ279254) and all 10 exons of WT1 (the gene encoding Wilms tumor 1 protein; GenBank accession no. NM_000378). Exons were amplified by using polymerase chain reaction, as described previously, 19, 20 and products were screened for sequence alteration by using conformation-sensitive gel electrophoresis. 21, 22 Molecular analysis also was simultaneously performed in all participants by using direct sequencing of all 8 exons of the NPHS2 gene and exons 8 and 9 of the WT1 gene at the Department of Pediatrics and Human Genetics, University of Michigan (courtesy of Professor Friedhelm Hildebrandt).
Protocol
Eligible patients were randomly assigned to receive treatment with either tacrolimus or CsA. Randomization lists using permuted blocks of variable size were computer generated off-site by a colleague not involved in the study. Allocates of individual patients were sealed in serially numbered opaque envelopes that were opened at randomization. Therapy with tacrolimus was initiated at a dose of 0.1 to 0.2 mg/kg/d (Pangraf; Panacea, Mumbai, India; 0.5-and 1-mg capsules) or CsA at 5 to 6 mg/kg/d (Panimun Bioral; Panacea; 25-and 50-mg capsules, 100-mg/mL suspension) in 2 divided doses before meals. The medication was given for 12 months unless the patient exited the study because of treatment failure. Patients in both groups received oral prednisolone (on alternate days) at a dose of 1 mg/kg for 6 months, followed by 0.5 mg/kg for the next 6 months, and enalapril (0.2 to 0.3 mg/kg/d). If required for blood pressure control, 23 the dose of enalapril was increased (0.4 to 0.5 mg/kg) or additional treatment was instituted (amlodipine, 0.1 to 0.3 mg/kg/d). Participants with serum cholesterol levels greater than 200 mg/dL were treated with atorvastatin (5 to 10 mg/d). All patients received daily supplements of calcium carbonate (250 to 500 mg) and vitamin D. Trough (12-hour) levels of tacrolimus and CsA were measured by using microparticle enzyme immunoassay and radioimmunoassay, respectively, at 2 weeks and 6 months during relapses or if they showed persistent nephrotoxicity. The desired level for tacrolimus was 5 to 8 ng/mL, and for CsA, 100 to 150 ng/mL; lower levels were accepted if patients were in remission.
Follow-up
Follow-up visits were scheduled fortnightly for 1 month and then every month. Physical examination and screening for side effects were performed at each visit. Laboratory evaluation included urinalysis (spot Up/Uc ratio) and estimation of blood levels of glucose, creatinine, electrolytes, albumin, transaminases, alkaline phosphatase, and lipids. Treatment adherence was assessed by means of pill count of the returned packs; a 1-month supply of the medication was provided. At 12 months, a photograph of the patient's teeth was graded by a blinded observer as: (1) none, (2) mild gingival overgrowth, (3) moderate overgrowth (involving half the crown), and (4) severe overgrowth (more than half the crown). 24 A picture of the back was assessed for hypertrichosis. Reversible nephrotoxicity was defined as an increase in serum creatinine level greater than 50% more than baseline that improved after reducing the dose of CsA or tacrolimus by 50% for 15 days. Persistent nephrotoxicity was defined as a similar increase in serum creatinine level that persisted despite dose reduction for 15 days. 25 The dose was also decreased if transaminase levels were greater than 150 IU/L, bilirubin level was greater than 2.5 mg/dL, trough CsA level was greater than 200 ng/mL, and tacrolimus level was greater than 10 ng/mL.
The occurrence of complete or partial remission after 6 months of treatment was considered a favorable response. Complete remission was defined as the absence of proteinuria (Up/Uc ratio Ͻ 0.2 g/g) and normal serum albumin level of 2.5 g/dL or greater; partial remission, as nonnephrotic proteinuria (Up/Uc ratio of 0.2 to 2.0 g/g) and normal serum albumin level; and nonresponse was persistent nephrotic-range proteinuria (Up/Uc ratio Ͼ2 g/g) or hypoalbuminemia with albumin less than 2.5 g/dL. Treatment failure was defined in patients showing nonresponse despite 6 months of treatment, persistent nephrotoxicity, or death. Patients who achieved remission, but experienced relapse (urine protein of 3ϩ for Ͼ 3 consecutive days, Up/Uc ratio Ͼ 2) were treated with prednisolone at 2 mg/kg/d until remission (maximum, 3 weeks), followed by 1.5 mg/kg on alternate days for 4 weeks, with tapering.
Analysis
The primary end point was comparison of the proportion of patients achieving complete or partial remission at the end of 6 months of therapy. Secondary outcome variables included time to achieve remission, proportion of participants in remission at 12 months, frequency of relapses, and side effects. Glomerular filtration rate was estimated at 12 months by using the Schwartz formula 17 and plasma clearance of technetium-labeled diethylene triamine pentaacetic acid.
Analyses were performed on an intention-to-treat basis. Data were analyzed using Stata, version 9.1 (StataCorp, College Station, TX). Continuous data are presented as mean, 95% confidence interval (CI), and range unless otherwise stated. Categorical variables were analyzed using 2 or Fischer exact test, and relative risk (RR) with 95% CI was calculated. Continuous variables were compared using ttest. Kaplan-Meier analysis was used to determine the probability of nonresponse to therapy in relation to time. A Cox proportional hazard model was performed to determine the effect of treatment on remission and was expressed as hazard ratio (HR). The assumption of proportional hazards was checked by using log-log survival curves, observed versus expected survival curves, and Schoenfeld residuals.
RESULTS
Of 58 patients assessed, 17 were excluded (14 did not meet eligibility criteria, and 3 did not consent; Fig 1) . Of participants randomly assigned, 21 were assigned to receive treatment with tacrolimus, and 20, with CsA. There was no loss to follow-up, and all patients were included in the analysis. Protocol deviation was present in 3 patients (2 in the tacrolimus and 1 in the CsA group) who continued to receive medication despite nephrotic-range proteinuria at 6 months because serum albumin level was 2.5 g/dL or greater.
Baseline Characteristics
There were no differences in the 2 groups in baseline clinical, laboratory, and histological features (Table 1) . Seventeen patients (10 in the tacrolimus and 7 in the CsA group) had previously received treatment with oral or IV cyclophosphamide (n ϭ 14), IV methylprednisolone or dexamethasone (n ϭ 8), and mycophenolate mofetil (n ϭ 1) without success. At the time of inclusion, all participants were edematous and had nephrotic-range proteinuria and hypoalbuminemia.
Therapy with tacrolimus was started at a mean daily dose of 0.12 mg/kg (95% CI, 0.11 to 0.13; range, 0.1 to 0.16 mg/kg), and CsA, at 5.02 mg/kg (95% CI, 4.91 to 5.13; range, 4.7 to 5.5 mg/kg). The respective doses at the end of 12 months of therapy were 0.10 mg/kg/d (95% CI, 0.09 to 0.11; range, 0.05 to 0.15 mg/kg/d) and 4.07 mg/kg/d (95% CI, 3.60 to 4.54; range, 2.5 to 5.5 mg/kg/d). Mean trough levels for tacrolimus and CsA 2 weeks after starting the medication were 4.6 ng/mL (95% CI, 3.9 to 5.3; range, 2.4 to 8.1 ng/mL) and 124.8 ng/mL (95% CI, 105.7 to 143.8; range, 66 to 231 ng/mL), respectively.
Response After 6 and 12 Months of Therapy
At the end of 6 months, remission occurred in 18 patients (85.7%) on tacrolimus therapy (9 complete and 9 partial) compared with 16 patients (80%) on CsA therapy (10 complete and 6 partial). The likelihood of remission was similar in patients receiving tacrolimus and CsA at 6 (RR, 1.07; 95% CI, 0.81 to 1.41) and 12 months (RR, 1.14; 95% CI, 0.84 to 1.55; Table 2 ). Figure 2 shows the probability of nonresponse in relation to time. At 52 weeks, proportions of patients showing nonresponse in those treated with tacrolimus and CsA were 9.5% (95% CI, 1.6 to 26.1) and 15% (95% CI, 3.7 to 33.4), respectively. The rate of complete or partial remission was 1.23 times greater for those treated with tacrolimus compared with CsA (hazard ratio, 1.23; 95% CI, 0.64 to 2.37; P ϭ 0.5). Median times to complete or partial remission were similar at 8 and 12 weeks in the tacrolimus and CsA groups, respectively. At 2 weeks, trough levels of tacrolimus were similar in patients in remission compared with those with nonresponse (P ϭ 0.6). Similarly, blood levels of CsA in patients with remission were similar to those with nonresponse (P ϭ 0.9).
Of 23 patients with initial resistance, 1 patient had heterozygous substitution of guanine to adenine (c.686G¡A; nucleotide numbering based on the translation initiation codon at position ϩ1) leading to an amino acid change of arginine to glutamine at amino acid 229 (p.Arg229Gln; protein alteration inferred based on DNA sequence) and 1 had a compound heterozygous substitution comprising c.686G¡A and c.965G¡C (which leads to an amino acid change of arginine to proline at residue 322 [p.Arg322Pro]) of the NPHS2 gene. The former achieved partial remission and the latter had complete remission on tacrolimus therapy. A heterozygous silent sequence variant, c.954T¡C (p.Ala318Ala), was found in 1 patient each in the tacrolimus and CsA groups. Both had initial steroid resistance, but showed complete remission with therapy. No patient with late steroid resistance showed sequence variations involving the WT1 and NPHS2 genes.
Relapses
Two patients (both with MCD) of the 18 who achieved remission after treatment with tacrolimus experienced 3 relapses. Of 16 patients in remission on CsA therapy, 8 (5 MCD, 2 FSGS, and 1 mesangioproliferative glomerulonephritis) experienced 13 relapses. A greater proportion of patients receiving CsA experienced relapse compared with tacrolimus (RR, 4.5; 95% CI, 1.1 to 18.2; P ϭ 0.01). All relapses except 1 were steroid sensitive. Mean durations of therapy at the time of relapse were 38 weeks (range, 32 to 
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44 weeks) in the tacrolimus group and 26 weeks (range, 12 to 40 weeks) in the CsA group. Mean trough levels of medications at relapse were 5.2 ng/mL (range, 2.2 to 8.2 ng/mL) and 107.4 ng/mL (range, 67.7 to 166 ng/mL) for tacrolimus and CsA, respectively. These levels were similar to those in patients with no relapses.
Other Outcome Variables
At 12 months (Table 3) , patients receiving tacrolimus had nonsignificantly greater blood levels of albumin. Although participants in both groups showed significant decreases in blood levels of cholesterol, the decrease was greater in those receiving tacrolimus. After 12 months of therapy, estimated glomerular filtration rate decreased significantly in both groups; differences between groups were not significant (P ϭ 0.1). Subgroup analysis showed that therapy with CsA was more likely to achieve complete remission in patients with late resistance (8 of 9 patients) compared with initial resistance (3 of 11 patients; P ϭ 0.009). A similar pattern was not found in patients receiving tacrolimus. Post hoc analy- sis of data showed that participants who achieved remission (n ϭ 35) had lower mean Up/Uc ratios at baseline compared with those with nonresponse (n ϭ 6; P ϭ 0.03). The occurrence of remission was not related to other clinical or histological features, medication used, or its levels.
Treatment failure in patients on tacrolimus therapy (3 patients) included 1 each with persistent nephrotoxicity (at 8 weeks of therapy) and nonresponse (trial deviate at 6 months); 1 patient with complete remission at 8 weeks died because of severe pneumonia and sepsis at 8 months. Medication was discontinued in 5 patients receiving CsA, including 2 each with persistent nephrotoxicity (at 12 weeks and 8 months of therapy) and nonresponse (both at 6 months) and 1 with secondary resistance (at 7 months; Fig 1) .
Figure 2.
Kaplan-Meier survival curve shows the probability of nonresponse during 12 months of treatment with cyclosporine (CsA) or tacrolimus (Tac). The number of patients at risk is given at the bottom of the graph. Abbreviation: CI, confidence interval. Note: Values expressed as mean (95% confidence interval) [range] . Conversion factors for units: blood creatinine in mg/dL to mol/L, ϫ88.4; albumin in g/dL to g/L, ϫ10; cholesterol in mg/dL to mmol/L, ϫ0.0259; glucose in mg/dL to mmol/L, ϫ0.05551; GFR in mL/min/1.73 m 2 to mL/s/1.73 m 2 , ϫ0.01667. Abbreviations: DTPA, diethylene triamine pentaacetic acid; GFR, glomerular filtration rate. *Participants not included in analysis: tacrolimus, 2 (persistent nephrotoxicity, 1; death, 1); and cyclosporine, 4 (persistent nephrotoxicity, 2; no response, 2). †Decrease in GFR over 12 months of therapy.
Side Effects
Nephrotoxicity was seen in 8 and 12 patients treated with tacrolimus and CsA, respectively. The toxicity was usually reversible (Table 4) . No patient showed new-onset hypertension, although the dose of enalapril was increased to treat hypertension in 2 participants in each group. Moderate gingival hypertrophy and hypertrichosis were common in patients on CsA therapy, and diarrhea was seen in patients receiving tacrolimus. There were transient increases in transaminase levels not requiring reduction of dose in 5 and 6 patients in the tacrolimus and CsA groups, respectively. Blood glucose and potassium levels were within normal limits.
DISCUSSION
This is the first randomized controlled trial comparing the efficacy and safety of tacrolimus with CsA in patients with idiopathic SRNS. A significant proportion of participants had previously failed to respond to treatment with IV/oral cyclophosphamide or IV corticosteroids. At the end of 6 months, complete and partial remissions were seen in 85.7% and 80% patients treated with tacrolimus and CsA, respectively. At the end of 12 months of therapy, the probability of not achieving complete or partial remission was 9.5% in the tacrolimus group and 15.0% in the CsA group. Our findings indicate that therapy with tacrolimus or CsA is comparable in inducing complete or partial remission in most patients with SRNS. Although not all experienced complete remissions, we believe that the occurrence of even partial response is useful in the long term. Similar response rates, ranging from 60% to 70%, have been reported after therapy with CsA. 8, 9, 26 A relatively greater response in the present study might be caused by inclusion of patients with both initial and late resistance, heterogeneous renal histological characteristics, and cotherapy with enalapril and prednisolone. Similar findings from uncontrolled studies suggest that tacrolimus is effective in achieving complete or partial remission in 85% to 95% of patients. 16, 27, 28 In the present study, we did not target prefixed levels of the medication. Although we aimed for trough levels of tacrolimus and CsA between 5 and 8 ng/mL and 100 to 150 ng/mL, respectively, lower levels were accepted if the patients were in remission. The mean daily dose of tacrolimus ranged between 0.10 and 0.12 mg/kg, and the trough level at 2 weeks was 4.6 ng/mL. Other investigators have used greater (0.15 to 0.37 mg/kg) doses of tacrolimus and attained greater levels (8.3 to 10.3 ng/mL). 15, 16, 27, 28 Similarly, dosages and blood levels of CsA were lower compared with other reports. 11 It is noteworthy that despite lower dosage and lower trough levels, 85.7% of patients on tacrolimus therapy and 75% on CsA therapy were in remission at the end of 12 months. It is speculated that the use of lower doses of medications may have implications in minimizing their side effects.
Previous reports suggest that 10% to 76% of patients experience relapse after cessation of treatment with calcineurin inhibitors. 10, 15, 27 However, there is limited information about occurrence of relapses during therapy. In a retrospective analysis of children with SRNS, 20% of participants receiving tacrolimus experienced relapse compared with 11% in the present study. 16 Results from the present study show that the relapse rate during treatment was significantly greater with CsA compared with tacrolimus. The trigger for most relapses was an upper respiratory tract infection, and the relapses responded to treatment with daily corticosteroids. In the present study, patients in both groups showed decrease in blood cholesterol levels, although the reduction was significantly greater with tacrolimus compared with CsA. Because dyslipidemia is a risk factor for atherosclerosis, cardiovascular mortality, and chronic kidney disease, its control after the use of either of the calcineurin inhibitors is promising. The relative long-term benefits of tacrolimus compared with CsA in this respect need to be examined further.
12
Sequence alteration involving the NPHS2 gene have been reported in 20% to 30% of patients with idiopathic SRNS. 29 In previous studies, none of the patients with a homozygous or compound heterozygous mutation in the NPHS2 achieved complete remission on CsA therapy. 29, 30 Ruf et al 29 reported partial response in 17% of patients with SRNS treated with CsA. In the present study, no participant had a homozygous NPSH2 mutation, and 1 had a compound heterozygous mutation. The latter achieved complete remission after treatment with tacrolimus. The significance of heterozygous sequence variants for the disease phenotype remains unclear. 29 The R229Q (p.Arg229Gln) mutation alone is insufficient to cause FSGS, but appears to enhance susceptibility to renal injury in a homozygous or compound heterozygote state. 22 Additional studies are required to evaluate the role of calcineurin inhibitors in patient with SRNS and homozygous or compound heterozygous sequence alterations in NPHS2. Similar to previous observations, we found that no patient with late steroid resistance had sequence alterations involving the NPHS2 or WT1 genes. 31 Nephrotoxicity, an important side effect of treatment with calcineurin inhibitors, was monitored closely during this study. A proportion of patients showed evidence of acute nephrotoxicity that reversed after reduction in the dose of calcineurin inhibitors. All these patients remained in remission, and no further episodes of nephrotoxicity were observed. The risk of persistent nephrotoxicity and decrease in glomerular filtration rate at 12 months was similar in patients treated with tacrolimus and CsA, similar to that noted by other investigators.
32
Cosmetic side effects, including gingival hypertrophy, hypertrichosis, and acne, were found in a significant proportion of children treated with CsA (Table 4) . Mahmoud et al 10 reported gum hyperplasia (20%) and hypertrichosis (49%) as the most frequent side effects observed with CsA therapy. The findings of increased risks of diarrhea and hypercholesterolemia after treatment with tacrolimus and CsA confirm those by other investigators, respectively. 12,13 Transplant recipients receiving tacrolimus, especially those with high trough levels, are considered at risk of new-onset diabetes. 13 In an observational study, 9% of children with SRNS on tacrolimus therapy showed hyperglycemia. 28 The use of a lower dose and lower drug levels might explain the absence of glucose intolerance or new-onset diabetes in our patients.
The chief limitation of this study was that a small number of patients with SRNS were recruited, reducing its power and strength of conclusions. Although the primary outcome was similar in patients receiving treatment with tacrolimus or CsA, statistically significant differences with wide CIs were found in some secondary outcomes. The study population was composed of clinically and histologically heterogeneous patients from a single center with short follow-up. Patients with late resistance are likely to respond better to therapy and favorably impact on the results of treatment. Monitoring drug levels was not rigorous. Finally, although achievement of complete or partial remission is assumed to reduce the risk of progressive kidney disease, the long-term benefits and safety of these agents was not examined. Despite these limitations, this is the first prospective randomized controlled trial comparing 2 promising medications for treatment of patients with SRNS. Genetic studies were performed in all patients at inclusion, although the results did not result in their exclusion from the study. There was close monitoring for side effects, minimal trial deviates, and no patient was lost to follow-up.
Findings from this study suggest that therapy with tacrolimus or CsA in combination with low-dose steroids shows similar efficacy in inducing remission in a considerable proportion of patients with SRNS. Although patients receiving tacrolimus showed lower relapse rates, decreased blood levels of cholesterol, and lack of cosmetic side effects, these were secondary end points. Although therapy with tacrolimus might be considered a reasonable alternative to CsA for patients with idiopathic SRNS, adequately powered studies with longer follow-up are necessary to confirm the relative benefits of prolonged therapy with these agents. It also is important to examine whether the remission induced with tacrolimus or CsA is sustained at lower doses or replacement with agents that are not nephrotoxic.
